Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05737940 | A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 | PHASE2 | COMPLETED | 260 | — | — | Apr 24, 2023 | Aug 25, 2025 | Sep 24, 2025 | 60 | United States, Austria +12 |
To evaluate the effect of AZD3427 on PVR parameter compared with placebo as measured by right heart catheterization (RHC) after 24 weeks of treatment in participants with HF and PH Group 2.
| Arm | Type | Description |
|---|---|---|
| AZD3427 Dose A | EXPERIMENTAL | The participants will receive single dose of AZD3427 Dose A every 2 weeks for 24 weeks from Day 1 to Day 155. |
| AZD3427 Dose B | EXPERIMENTAL | The participants will receive single dose of AZD3427 Dose B every 2 weeks for 24 weeks from Day 1 to Day 155. |
| AZD3427 Dose C | EXPERIMENTAL | The participants will receive single dose of AZD3427 Dose C every 2 weeks for 24 weeks from Day 1 to Day 155. |
| Placebo | PLACEBO_COMPARATOR | The participants will receive single dose of placebo every 2 weeks for 24 weeks from Day 1 to Day 155. |
| Name | Type | Description |
|---|---|---|
| AZD3427 | DRUG | The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks. |
| Placebo | DRUG | The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks. |
Inclusion criteria: 1. Participant must be ≥ 18 years of age inclusive. 2. Participants must have a pre-existing diagnosis of HF, NYHA function class (FC) II to IV, and a pre-existing diagnosis of PH-LHD or likely or intermediate probability of Pulmonary hypertension due to left heart disease (PH-L...